Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
CANbridge Pharmaceuticals Inc. ( (HK:1228) ) just unveiled an update.
CANbridge Pharmaceuticals Inc. has scheduled a board meeting for March 30, 2026 to review and approve the annual results for the year ended December 31, 2025 and to authorize their publication. The announcement signals the forthcoming release of full-year financial and operational performance, an important disclosure event for shareholders and other market participants tracking the company’s progress.
The composition of the board, including executive, non-executive and independent non-executive directors, is reiterated in the notice, underscoring the company’s adherence to corporate governance norms required of a Hong Kong-listed entity. This formal step aligns CANbridge with regulatory expectations on timely financial reporting and provides investors with a clear timetable for upcoming earnings-related information.
The most recent analyst rating on (HK:1228) stock is a Buy with a HK$3.00 price target. To see the full list of analyst forecasts on CANbridge Pharmaceuticals Inc. stock, see the HK:1228 Stock Forecast page.
More about CANbridge Pharmaceuticals Inc.
CANbridge Pharmaceuticals Inc., incorporated in the Cayman Islands and listed on the Hong Kong Stock Exchange, operates in the biopharmaceutical industry. The company is governed by a board comprising an executive director, non-executive directors and independent non-executive directors, reflecting a standard corporate governance structure for a listed pharma issuer.
Average Trading Volume: 3,759,001
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.26B
See more insights into 1228 stock on TipRanks’ Stock Analysis page.